[211]
UPPER GASTROINTESTINAL TUMOUR STREAM: OESOPHAGOGASTRIC CANCER
[193,7 KB]
From [www.health.vic.gov.au] Last viewed: 26.08.2005
[212]
Gastrointestinal Cancer Program
[59,4 KB]
From [www.fccc.edu] Last viewed: 26.08.2005
[213]
Gastrointestinal Cancer Program
[105,0 KB]
From [www.fccc.edu] Last viewed: 26.08.2005
[214]
Screening and surveillance for upper and lower gastrointestinal cancer
[61,9 KB]
From [www.rcpe.ac.uk] Last viewed: 26.08.2005
[215]
Long-acting Repeatable (Lar) Octreotide for Clinical Management of ...
[74,8 KB]
From [www.touchbriefings.com] Last viewed: 26.08.2005
[216]
Nutrition and Diet in the Development of Gastrointestinal Cancer
From [www.biomedcentral.com] Last viewed: 26.08.2005
[217]
The Epidermal Growth Factor Receptor As a Target for ...
From [www.biomedcentral.com] Last viewed: 26.08.2005
[218]
Anti-Cancer Treatment - 12th International Congress Third ...
From [www.biomedcentral.com] Last viewed: 26.08.2005
[219]
Does asbestos exposure cause gastrointestinal cancer?
[21,8 KB]
From [www.springerlink.com] Last viewed: 26.08.2005
[220]
Raman spectra of single cell from gastrointestinal cancer patients
[106,4 KB]
From [www.wjgnet.com] Last viewed: 02.07.2005
[221]
The new DR-70 immunoassay detects cancer of the gastrointestinal ...
[131,9 KB]
From [www.amdlaustralia.com.au] Last viewed: 02.07.2005
[222]
Gastrointestinal Cancer Drugs in the Pipeline
[81,1 KB]
From [hemonctoday.com] Last viewed: 02.07.2005
[223]
Newer Approaches to the Prevention of Gastrointestinal Cancer
[235,1 KB]
From [kacp.or.kr] Last viewed: 02.07.2005
[224]
Long-acting Repeatable (Lar) Octreotide for Clinical Management of ...
[74,8 KB]
From [www.bbriefings.com] Last viewed: 02.07.2005
[225]
THE PHASE 2 AND 3 GASTROINTESTINAL CANCER PIPELINE
[226,4 KB]
From [www.hemonctoday.com] Last viewed: 02.07.2005
[226]
Mortality in lung and gastrointestinal cancer among shipyard workers
[22,1 KB]
From [www.springerlink.com] Last viewed: 02.07.2005
[227]
Distant Peritoneal Metastasis to a Mesh-Plug Prosthesis in a ...
[21,7 KB]
From [www.springerlink.com] Last viewed: 02.07.2005
[228]
Book Reviews: Management of Upper ...
[20,0 KB]
From [www.springerlink.com] Last viewed: 02.07.2005
[229]
Growth inhibition of human gastrointestinal cancer cells by ...
[22,9 KB]
From [www.springerlink.com] Last viewed: 02.07.2005
[230]
ASCO 2003 XYOTAX in gastrointestinal cancer
From [www.novuspharma.com] Last viewed: 02.07.2005
[231]
A Multidisciplinary Approach to Gastrointestinal Bleeding in ...
[235,6 KB]
From [www.supportiveoncology.net] Last viewed: 28.05.2005
101
V
OLUME
3, N
UMBER
2
¦
M
ARCH
/A
PRIL
2005
www.SupportiveOncology.net
J Support Oncol 2005;3:101–110
© 2005 Elsevier Inc. All rights reserved.
R E V I E W
A Multidisciplinary Approach to
Gastrointestinal Bleeding in
Cancer Patients
John J.Imbesi,MD,and Robert C.Kurtz,MD
Abstract Gastrointestinal bleeding remains one of the most challenging
areas in medicine today,especially in the patient with cancer .New tech-
niques and technology have added much to the diagnosis and manage-
ment of gastrointestinal bleeding.Although gastroenterologists remain
at the center of the evaluation of these patients, the incorporation of
new techniques has meant that interventional radiologists and nuclear
medicine specialists often have important roles in assessing ...
[232]
Long-acting Repeatable (Lar) Octreotide for Clinical Management of ...
[74,8 KB]
From [bbriefings.com] Last viewed: 28.05.2005
Long-acting Repeatable (Lar) Octreotide for Clinical
Management of Gastrointestinal Cancer
a report by
Alessandra Mosca
Managing Director, Department of Clinical Oncology,
San Luigi Hospital, Orbassano, Italy
on behalf of Novartis Pharma AG
e-mail: ale.mos@libero.it
Page 2
O C T R E O T I D E L A R I N G A S T R O I N T E S T I N A L T U M O U R S
2
Abstract
Octreotide represents a novel approach to the treatment of various endocrinological
and oncological disorders. Its effects are mediated through its interaction with the
somatostatin receptor subtype 2, and to a lesser extent subtypes 5 and 3, and
subsequent effects on hormone secretion. A long-acting repeatable (LAR)
formulation of octreotide is now available. It is administered by intramuscular injection
every 4 weeks. Results to date suggest that octreotide LAR appears ...
[233]
Long-acting Repeatable (Lar) Octreotide for Clinical Management of ...
[132,5 KB]
From [bbriefings.com] Last viewed: 28.05.2005
Long-acting Repeatable (Lar) Octreotide for Clinical
Management of Gastrointestinal Cancer
a report by
Alessandra Mosca
Managing Director, Department of Clinical Oncology,
San Luigi Hospital, Orbassano, Italy
on behalf of Novartis Pharma AG
e-mail: ale.mos@libero.it
Page 2
O C T R E O T I D E L A R I N G A S T R O I N T E S T I N A L T U M O U R S
2
Abstract
Octreotide represents a novel approach to the treatment of various endocrinological
and oncological disorders. Its effects are mediated through its interaction with the
somatostatin receptor subtype 2, and to a lesser extent subtypes 5 and 3, and
subsequent effects on hormone secretion. A long-acting repeatable (LAR)
formulation of octreotide is now available. It is administered by intramuscular injection
every 4 weeks. Results to date suggest that octreotide LAR appears ...
[234]
Real-time endoscopic fluorescence imaging for early cancer ...
[3164,5 KB]
From [www.gis.usu.edu] Last viewed: 28.05.2005
Bioimaging 6 (1998) 151–165. Printed in the UK
PII: S0966-9051(98)97820-0
Real-time endoscopic fluorescence
imaging for early cancer detection in
the gastrointestinal tract
Haishan Zeng † , Alan Weiss ‡ , Richard Cline § and
Calum E MacAulay †
† Cancer Imaging Department, British Columbia Cancer Research Centre,
601 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 1L3
‡ British Columbia Cancer Agency–Vancouver Clinic, 600 West 10th Avenue,
Vancouver, British Columbia, Canada V5Z 4E6
§ Xillix Technologies Corporation, 300–13775 Commerce Parkway, Richmond,
British Columbia, Canada V6V 2V4
Submitted 20 July 1998, accepted 22 September 1998
Abstract. The utility of autofluorescence imaging for early lung cancer detection has
been previously demonstrated. The aim of this work is to extend the use of real-time
autofluorescence imaging to the ...
[235]
Gastrointestinal Perforation and Cancer Therapy: Managing Risk to ...
[7,6 KB]
From [content.karger.com] Last viewed: 28.05.2005
Novartis International AG
Novartis Communications
CH-4002 Basel
Switzerland
Tel + 41 61 324 2200
Fax + 41 61 324 3300
Internet address:
http://www.novartis.com
*In the US: Gleevec
®
(imatinib mesylate)
1/2
MEDIA RELEASE
•
COMMUNIQUE AUX MEDIAS
•
MEDIENMITTEILUNG
Glivec
®
approved in Japan for treatment of life-threatening
gastrointestinal cancer
Basel, Switzerland, 17 July 2003 – Novartis announced today that health authorities in Japan
have approved Glivec
®
(imatinib)* for the treatment of patients with KIT (CD117) positive
gastrointestinal stromal tumors (GISTs), a life-threatening cancer . Historically, GISTs have
been very difficult to treat due to their resistance to treatment with available chemotherapy and
radiation therapy. Previously, ...
[236]
Influence of Gastrointestinal Hormones on Tumor Microcirculation ...
[7,6 KB]
From [content.karger.com] Last viewed: 28.05.2005
Novartis International AG
Novartis Communications
CH-4002 Basel
Switzerland
Tel + 41 61 324 2200
Fax + 41 61 324 3300
Internet address:
http://www.novartis.com
*In the US: Gleevec
®
(imatinib mesylate)
1/2
MEDIA RELEASE
•
COMMUNIQUE AUX MEDIAS
•
MEDIENMITTEILUNG
Glivec
®
approved in Japan for treatment of life-threatening
gastrointestinal cancer
Basel, Switzerland, 17 July 2003 – Novartis announced today that health authorities in Japan
have approved Glivec
®
(imatinib)* for the treatment of patients with KIT (CD117) positive
gastrointestinal stromal tumors (GISTs), a life-threatening cancer . Historically, GISTs have
been very difficult to treat due to their resistance to treatment with available chemotherapy and
radiation therapy. Previously, ...
[237]
Pretherapeutic assessment of resectability in patients with upper ...
From [www.springerlink.com] Last viewed: 28.05.2005
101
V
OLUME
3, N
UMBER
2
¦
M
ARCH
/A
PRIL
2005
www.SupportiveOncology.net
J Support Oncol 2005;3:101–110
© 2005 Elsevier Inc. All rights reserved.
R E V I E W
A Multidisciplinary Approach to
Gastrointestinal Bleeding in
Cancer Patients
John J.Imbesi,MD,and Robert C.Kurtz,MD
Abstract Gastrointestinal bleeding remains one of the most challenging
areas in medicine today,especially in the patient with cancer .New tech-
niques and technology have added much to the diagnosis and manage-
ment of gastrointestinal bleeding.Although gastroenterologists remain
at the center of the evaluation of these patients, the incorporation of
new techniques has meant that interventional radiologists and nuclear
medicine specialists often have important roles in assessing ...
[238]
The gastroenterologist and gastrointestinal cancer
[21,0 KB]
From [www.springerlink.com] Last viewed: 16.04.2005
Version 1.0
08/12/1999
June 20, 2003
EORTC Data Center
Av. E. Mounier 83/11
1200 Brussels, Belgium
Direct phone: + 32 2 774 16 11
Fax: + 32 2 772 35 45
EORTC GASTROINTESTINAL TRACT CANCER AND
RADIOTHERAPY GROUP
INTEREST FORM
Randomised phase II/III study comparing Gemcitabine followed by Gemcitabine plus concomitant
radiation (50.4 Gy) versus control after curative pancreaticoduodenectomy for pancreatic head cancer
“40013/22012”
I, the undersigned declare that I have read the proposed study outline and I am interested in
entering patients in the study
YES
NO
I understand that this procedure is not binding me/my center to the study but I realize that
preliminary interest will be used to evaluate the potential accrual of the proposed trial and set up
the study infrastructure
Expected accrual per YEAR:
...
[239]
Cytostatic activity on tumour cells of monocytes from patients ...
[22,0 KB]
From [www.springerlink.com] Last viewed: 16.04.2005
Version 1.0
08/12/1999
June 20, 2003
EORTC Data Center
Av. E. Mounier 83/11
1200 Brussels, Belgium
Direct phone: + 32 2 774 16 11
Fax: + 32 2 772 35 45
EORTC GASTROINTESTINAL TRACT CANCER AND
RADIOTHERAPY GROUP
INTEREST FORM
Randomised phase II/III study comparing Gemcitabine followed by Gemcitabine plus concomitant
radiation (50.4 Gy) versus control after curative pancreaticoduodenectomy for pancreatic head cancer
“40013/22012”
I, the undersigned declare that I have read the proposed study outline and I am interested in
entering patients in the study
YES
NO
I understand that this procedure is not binding me/my center to the study but I realize that
preliminary interest will be used to evaluate the potential accrual of the proposed trial and set up
the study infrastructure
Expected accrual per YEAR:
...
[240]
GASTROINTESTINAL CANCER
[36,8 KB]
From [www.post-asco.be] Last viewed: 19.03.2005
GASTROINTESTINAL CANCER
Prof. Dr. E. Van Cutsem
Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium
Although the number of new phase 3 studies with
positive outcome presented at the meeting of the
American Society of Oncology in New-Orleans in
2004, that will influence daily practise, was lower in
2004 than in 2003, the 2004 meeting revealed again
very important new scientific information and new
clinical data. In the plenary session 2 studies on colon
cancer were presented:a population based case
control study showed that HMG CoA reductase
inhibitors are associated with a reduction in the risk of
colorectal cancer (abstract 1) and study on translatio-
nal research suggested a link between Quality of life
during chemotherapy for metastatic colorectal cancer
and genetic markers (abstract 5). Very large adjuvant
studies were reported ...
Found 373 documents
Page 8 of 13 Pages:
<< < 3 4 5 6 7 8 9 10 11 12 13 > >>
cancers
homepage
last week